The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
Introduction In this exclusive interview Kenneth Barr, Senior Vice President – Research Services at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery. With a deep focus on precision targeting and a track record of success in oncology and neurodegenerative diseases, Syngene leverages AI-powered […]
new
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
Introduction Biologics Outsourcing: From Option to Imperative The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science. But equally critical are the conversations around how […]
4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
Introduction In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity. The global specialty polymer market, valued at over $87 billion globally (2024), is fast becoming the backbone of innovations in clean energy, medical devices, and high-performance electronics. Nowhere is this shift more urgent than in […]
Elevating Patient Safety: Syngene’s Leadership in Nitrosamine Testing and Comprehensive Analytical Development Services
Introduction The pharmaceutical industry has been forced to reckon with the increasing discovery of nitrosamine impurities in drugs, compounds known for their carcinogenic potential. This became especially pronounced in 2018, when several widely used medications, such as Valsartan and Ranitidine, were recalled due to the presence of nitrosamines. Nitrosamines have since become a key focus […]
The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
Introduction The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases. However, as Elanco’s CEO, Jeff Simmons, highlights in a […]
SynWeaveâ„¢: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Introduction Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones. Biopharma companies require optimal clone yields to ensure maximum […]
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
Introduction The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light. However, these therapies are often very expensive, highlighting the ever-growing need for improved efficiency and productivity. One of the key levers in enhancing […]
Powering up Antibody Drug Conjugates with PROTACS
Introduction The past 20 years have brought a new generation of cancer therapeutics designed to target tumor cells or cellular processes involved with tumor cell growth. Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. However, challenges remain, such as linker breakdown, premature […]
Hyaluronic Acid: A wonder molecule for the cosmetic and pharma industries
Introduction Hyaluronic acid (HA) biopolymer is a naturally occurring material that helps retain moisture in the skin, eyes and lubricates the joints. However, with age, the body starts producing less and less of this material, resulting in conditions such as dry eyes, osteoarthritis, aging skin, and so on. Pharma and cosmetic industries realized that this […]